Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 10, 2014, Pages 3805-3810

  Hoshii, Takayuki ^a   Kasada, Atsuo ^a   Hatakeyama, Tomoki ^a   Ohtani, Masashi ^b   Tadokoro, Yuko ^a   Naka, Kazuhito ^a   Ikenoue, Tsuneo ^c   Ikawa, Tomokatsu ^d   Kawamoto, Hiroshi ^d,e   Fehling, Hans Joerg ^f   Araki, Kimi ^g   Yamamura, Ken Ichi ^g   Matsuda, Satoshi ^b   Hirao, Atsushi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d RIKEN Center for Integrative Medical Sciences   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f UNIVERSITY OF ULM   (Germany)

^g KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 6; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TAMOXIFEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CONTROLLED STUDY; GENE DELETION; HEMATOPOIESIS; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPHOPOIESIS; MOUSE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; ORGANOGENESIS; PHENOTYPE; PRE T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAPTOR; T LYMPHOCYTE; T LYMPHOCYTE ACUTE LYMPHOBLASTIC LEUKEMIA; THYMOCYTE; THYMUS ATROPHY; VIRAL GENE THERAPY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARRIER PROTEINS; CELL CYCLE; DNA PRIMERS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPHOPOIESIS; MICE; MODELS, IMMUNOLOGICAL; MULTIPROTEIN COMPLEXES; PRECURSOR CELLS, T-LYMPHOID; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84896304723     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1320265111     Document Type: Article

References (36)

1. Laplante M, Sabatini DM (2012) mTOR Signaling. Cold Spring Harb Perspect Biol 4(2): pii: a011593.
2. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121(2):179-193.
3. Berndt N, Hamilton AD, Sebti SM (2011) Targeting protein prenylation for cancer therapy. Nat Rev Cancer 11 (11):775-791.
4. Altman JK, Platanias LC (2008) Exploiting the mammalian target of rapamycin path way in hematologic malignancies. Curr Opin Hematol 15(2):88-94.
5. Teachey DT, Grupp SA, Brown VI (2009) Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malig nancies. Br J Haematol 145(5):569-580.
6. Gutierrez A, et al. (2009) High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114(3):647-650.
7. Guo W, et al. (2008) Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 453(7194):529-533.
8. Zhang J, et al. (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441(7092):518-522.
9. Yilmaz OH, et al. (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 (7092):475-482.
10. Magee JA, et al. (2012) Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 11(3): 415-428.
11. Kalaitzidis D, et al. (2012) mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell 11 (3):429-439.
12. Delgoffe GM, et al. (2011) The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 12(4):295-303.
13. Kang SA, et al. (2013) mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 341(6144):1236566.
14. Luo H, Duguid W, Chen H, Maheu M, Wu J (1994) The effect of rapamycin on T cell development in mice. Eur J Immunol 24(3):692-701.
15. Luche H, Weber O, Nageswara Rao T, Blum C, Fehling HJ (2007) Faithful activation of an extra-bright red fluorescent protein in "knock-in" Cre-reporter mice ideally suited for lineage tracing studies. Eur J Immunol 37(1):43-53.
16. Miyazaki M, et al. (2005) Polycomb group gene mel-18 regulates early T progenitor expansion by maintaining the expression of Hes-1, a target of the Notch pathway. J Immunol 174(5):2507-2516.
17. Hu MG, et al. (2009) A requirement for cyclin-dependent kinase 6 in thymocyte de velopment and tumorigenesis. Cancer Res 69(3):810-818.
18. Sicinska E, et al. (2003) Requirement for cyclin D3 in lymphocyte development and Tcell leukemias. Cancer Cell 4(6):451-461.
19. Powers SE, et al. (2012) Subnuclear cyclin D3 compartments and the coordinated regulation of proliferation and immunoglobulin variable gene repression. J Exp Med 209(12):2199-2213.
20. Sabnis AJ, et al. (2009) Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 7(3):e59.
21. Van Meter ME, et al. (2007) K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood 109(9): 3945-3952.
22. Chan IT, et al. (2004) Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113(4):528-538.
23. Braun BS, et al. (2004) Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 101(2): 597-602.
24. Zhang J, et al. (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380):157-163.
25. Kawamata S, Sakaida H, Hori T, Maeda M, Uchiyama T (1998) The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 91(2):561-569.
26. Nourse J, et al. (1994) Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372(6506):570-573.
27. Sarbassov DD, et al. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22(2):159-168.
28. Wei G, et al. (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10(4):331-342.
29. Sawai CM, et al. (2012) Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell 22(4):452-465.
30. Sicinska E, et al. (2006) Essential role for cyclin D3 in granulocyte colony-stimulating factor-driven expansion of neutrophil granulocytes. Mol Cell Biol 26(21):8052-8060.
31. Hleb M, et al. (2004) Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes. J Biol Chem 279(30):31948-31955.
32. García-Morales P, et al. (2006) Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. Mol Cancer Ther 5(9):2172-2181.
33. Dowling RJ, et al. (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328(5982):1172-1176.
34. Lee K, et al. (2012) Vital roles of mTOR complex 2 in Notch-driven thymocyte dif ferentiation and leukemia. J Exp Med 209(4):713-728.
35. Foster DA, Toschi A (2009) Targeting mTOR with rapamycin: One dose does not fit all. Cell Cycle 8(7): 1026-1029.
36. Hoshii T, et al. (2012) mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest 122(6):2114-2129.